Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephapirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.84 |
| ▸ | MAPT | P10636 | 8/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | APEX1 | P27695 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CA5A | P35218 | 1/20 | 0.66 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephapirin SCHEMBL4190569 | 1.00 | NR1I2 (0.84) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL16072823 | 0.92 | NR1I2 (1.00) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL11844793 | 0.92 | NR1I2 (1.00) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL11844804 | 0.92 | NR1I2 (1.00) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL8194062 | 0.92 | NR1I2 (1.00) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL3205 | 0.92 | NR1I2 (1.00) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL9437555 | 0.91 | NR1I2 (0.98) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL151779 | 0.91 | NR1I2 (0.98) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL28932665 | 0.91 | NR1I2 (0.98) | NR1I2MAPTTDP1CYP3A4L3MBTL1 | |
| Cephapirin SCHEMBL10275188 | 0.86 | NR1I2 (0.88) | NR1I2MAPTTDP1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124758-B2 | Bacteria culture medium and applications thereof | SHANGHAI PROMOTON BIOTECHNOLOGY CO., LTD. (CN) | 2021-09-21 | — | — | US | claimed |
| EP-3018134-B1 | BACTERIA CULTURE MEDIUM AND USE THEREOF | SHANGHAI PROMOTON BIOTECHNOLOGY CO LTD (CN) | 2018-04-04 | — | — | EP | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| EP-3018134-A1 | BACTERIA CULTURE MEDIUM AND USE THEREOF | Shanghai Promoton Biotechnology Co., Ltd (CN) | 2016-05-11 | — | — | EP | claimed |
| US-20160097030-A1 | Bacteria Culture Medium and Applications Thereof | NANTONG BROTH BIOTECHNOLOGY CO., LTD (CN) | 2016-04-07 | — | — | US | claimed |
| CN-103396968-B | Bacteria culture medium and application thereof | SHANGHAI QIDONGYUAN BIOLOG SCIENT CO LTD | 2015-03-25 | — | — | CN | claimed |
| CN-103230366-B | Novel slow-release breast perfusion agent for preventing cow subclinical mastitis and preparation method thereof | CHINA ANIMAL HUSBANDRY COMMERICAL (GROUP) GEN. CORP. (CN) | 2014-10-01 | — | — | CN | claimed |
| CN-103396968-A | Bacteria culture medium and application thereof | SHANGHAI PROMOTON BIOLOG SCIENT CO LTD | 2013-11-20 | — | — | CN | claimed |
| CN-103230366-A | Novel slow-release breast perfusion agent for preventing cow subclinical mastitis and preparation method thereof | CHINA ANIMAL HUSBANDRY GROUP | 2013-08-07 | — | — | CN | claimed |
| CN-102020665-B | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2012-09-19 | — | — | CN | claimed |
| CN-101781317-B | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2012-03-28 | — | — | CN | claimed |
| CN-102020665-A | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2011-04-20 | — | — | CN | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| CN-101781317-A | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEU | 2010-07-21 | — | — | CN | claimed |
| US-20090325975-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-12-31 | — | — | US | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-2819699-B2 | CONTROLLED RELEASE COMPOSITIONS AND THEIR METHODS OF USE | Elanco New Zealand (NZ) | 2024-10-16 | — | — | EP | disclosed |
| CN-115664779-A | Method, device and equipment for detecting abnormal flow of industrial network and storage medium | 杭州安恒信息技术股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| US-11311582-B2 | Bacteriophage compositions and methods of use thereof | Locus Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11124758-B2 | Bacteria culture medium and applications thereof | SHANGHAI PROMOTON BIOTECHNOLOGY CO., LTD. (CN) | 2021-09-21 | — | — | US | disclosed |
| US-10828311-B2 | Controlled release compositions and their methods of use | BAYER NEW ZEALAND LIMITED (NZ) | 2020-11-10 | — | — | US | disclosed |
| EP-3694489-A2 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | Illustris Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-110228897-A | Drainage processing method and disintegrating system in waste pipe | 日立造船株式会社 | 2019-09-13 | — | — | CN | disclosed |
| EP-2819699-B1 | CONTROLLED RELEASE COMPOSITIONS AND THEIR METHODS OF USE | BAYER NEW ZEALAND LTD (NZ) | 2019-05-22 | — | — | EP | disclosed |
| WO-2019075263-A2 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | ILLUSTRIS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190105261-A1 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | ILLUSTRIS PHARMACEUTICALS, INC. | 2019-04-11 | — | — | US | disclosed |
| EP-3442488-A1 | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | Illustris Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190015475-A1 | CASEIN PEPTIDE FOR USE IN THE TREATMENT OF UTERINE INFECTIONS | MILEUTIS LTD. (IL) | 2019-01-17 | — | — | US | disclosed |
| US-20190008795-A1 | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | ILLUSTRIS PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | disclosed |
| EP-3018134-B1 | BACTERIA CULTURE MEDIUM AND USE THEREOF | SHANGHAI PROMOTON BIOTECHNOLOGY CO LTD (CN) | 2018-04-04 | — | — | EP | disclosed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| US-9861678-B2 | Casein peptide for use in the treatment of uterine infections | MILEUTIS LTD. (IL) | 2018-01-09 | — | — | US | disclosed |
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| WO-2017180788-A1 | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | ILLUSTRIS PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-9789115-B2 | Use of sigma ligands in opioid-induced hyperalgesia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-20170290778-A1 | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | ILLUSTRIS PHARMACEUTICALS, INC. | 2017-10-12 | — | — | US | disclosed |
| US-9782483-B2 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2017-10-10 | — | — | US | disclosed |
| EP-2560669-B2 | CASEIN PEPTIDE FOR USE IN THE TREATMENT OF UTERINE INFECTIONS | MILEUTIS LTD (IL) | 2017-10-04 | — | — | EP | disclosed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| US-20160367580-A1 | IMPROVED EXTENDED-ACTION TILMICOSIN AND USE THEREOF IN TREATMENT OF BOVINE RESPIRATORY DISEASE COMPLEX (BRD) AND IN DRY COW PERIOD | UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) | 2016-12-22 | — | — | US | disclosed |
| US-20160324915-A1 | Casein Peptide for Use in the Treatment of Uterine Infections | MILEUTIS LTD. (IL) | 2016-11-10 | — | — | US | disclosed |
| EP-3018134-A1 | BACTERIA CULTURE MEDIUM AND USE THEREOF | Shanghai Promoton Biotechnology Co., Ltd (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-20160097030-A1 | Bacteria Culture Medium and Applications Thereof | NANTONG BROTH BIOTECHNOLOGY CO., LTD (CN) | 2016-04-07 | — | — | US | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| CN-102933223-B | Casein peptides for the treatment of uterine infections | MILEUTIS LTD. (IL) | 2016-03-09 | — | — | CN | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| US-9220751-B2 | Casein peptide for use in the treatment of uterine infections | MILEUTIS LTD. (IL) | 2015-12-29 | — | — | US | disclosed |
| CN-103396968-B | Bacteria culture medium and application thereof | SHANGHAI QIDONGYUAN BIOLOG SCIENT CO LTD | 2015-03-25 | — | — | CN | disclosed |
| WO-2015021692-A1 | BACTERIA CULTURE MEDIUM AND USE THEREOF | 上海启动元生物科技有限公司 (CN) | 2015-02-19 | — | — | WO | disclosed |
| US-20150045337-A1 | CONTROLLED RELEASE COMPOSITIONS AND THEIR METHODS OF USE | Elanco New Zealand (NZ) | 2015-02-12 | — | — | US | disclosed |
| EP-2819699-A1 | CONTROLLED RELEASE COMPOSITIONS AND THEIR METHODS OF USE | Bayer New Zealand Limited (NZ) | 2015-01-07 | — | — | EP | disclosed |
| CN-104244983-A | Controlled release compositions and methods of use thereof | BAYER NEW ZEALAND LTD | 2014-12-24 | — | — | CN | disclosed |
| CN-103230366-B | Novel slow-release breast perfusion agent for preventing cow subclinical mastitis and preparation method thereof | CHINA ANIMAL HUSBANDRY COMMERICAL (GROUP) GEN. CORP. (CN) | 2014-10-01 | — | — | CN | disclosed |
| CN-103230366-B | Novel slow-release breast perfusion agent for preventing cow subclinical mastitis and preparation method thereof | CHINA ANIMAL HUSBANDRY COMMERICAL (GROUP) GEN. CORP. (CN) | 2014-10-01 | — | — | CN | disclosed |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-12-05 | — | — | US | disclosed |
| CN-103396968-A | Bacteria culture medium and application thereof | SHANGHAI PROMOTON BIOLOG SCIENT CO LTD | 2013-11-20 | — | — | CN | disclosed |
| WO-2013129944-A1 | CONTROLLED RELEASE COMPOSITIONS AND THEIR METHODS OF USE | BAYER NEW ZEALAND LIMITED (NZ) | 2013-09-06 | — | — | WO | disclosed |
| CN-103230366-A | Novel slow-release breast perfusion agent for preventing cow subclinical mastitis and preparation method thereof | CHINA ANIMAL HUSBANDRY GROUP | 2013-08-07 | — | — | CN | disclosed |
| CN-103230366-A | Novel slow-release breast perfusion agent for preventing cow subclinical mastitis and preparation method thereof | CHINA ANIMAL HUSBANDRY GROUP | 2013-08-07 | — | — | CN | disclosed |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| US-20130109634-A1 | Casein Peptide For Use In The Treatment Of Uterine Infections | MILEUTIS, LTD. (IL) | 2013-05-02 | — | — | US | disclosed |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-05-02 | — | — | US | disclosed |
| EP-2560669-A1 | CASEIN PEPTIDE FOR USE IN THE TREATMENT OF UTERINE INFECTIONS | Mileutis Ltd. (IL) | 2013-02-27 | — | — | EP | disclosed |
| CN-102933223-A | Casein peptides for the treatment of uterine infections | MILEUTIS LTD | 2013-02-13 | — | — | CN | disclosed |
| CN-101107015-B | Injection for mastitis | NIPPON ZENYAKU KOGYO KK | 2013-01-23 | — | — | CN | disclosed |
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-29 | — | — | US | disclosed |
| CN-102020665-B | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2012-09-19 | — | — | CN | disclosed |
| CN-102020665-B | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2012-09-19 | — | — | CN | disclosed |
| CN-102020665-B | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2012-09-19 | — | — | CN | disclosed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| CN-101781317-B | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2012-03-28 | — | — | CN | disclosed |
| CN-101781317-B | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2012-03-28 | — | — | CN | disclosed |
| CN-101781317-B | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2012-03-28 | — | — | CN | disclosed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | disclosed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011132191-A1 | CASEIN PEPTIDE FOR USE IN THE TREATMENT OF UTERINE INFECTIONS | MILEUTIS LTD. (IL) | 2011-10-27 | — | — | WO | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |
| CN-102020665-A | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2011-04-20 | — | — | CN | disclosed |
| CN-102020665-A | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2011-04-20 | — | — | CN | disclosed |
| CN-102020665-A | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD | 2011-04-20 | — | — | CN | disclosed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| CN-101781317-A | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEU | 2010-07-21 | — | — | CN | disclosed |
| CN-101781317-A | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEU | 2010-07-21 | — | — | CN | disclosed |
| CN-101781317-A | Method for preparing cephapirin benzathine | GUANGZHOU BAIYUNSHAN PHARMACEU | 2010-07-21 | — | — | CN | disclosed |
| US-20090325975-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-12-31 | — | — | US | disclosed |
| US-20090312380-A1 | NOVEL COMPOSITIONS AND METHODS | GENERICS [UK] LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| WO-2009120182-A2 | SULFO-POLYMER POWDER AND SULFO-POLYMER POWDER BLENDS WITH CARRIERS AND/OR ACTIVES | EASTMAN CHEMICAL COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | disclosed |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-07-16 | — | — | US | disclosed |
| US-20090163449-A1 | SULFO-POLYMER POWDER AND SULFO-POLYMER POWDER BLENDS WITH CARRIERS AND/OR ADDITIVES | EASTMAN CHEMICAL COMPANY (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2056875-A1 | NOVEL COMPOSITIONS AND METHODS | Generics (UK) Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| WO-2008026012-A1 | NOVEL COMPOSITIONS AND METHODS | GENERICS [UK] LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| CN-101107015-A | Injection for mastitis | NIPPON ZENYAKU KOGYO KK (JP) | 2008-01-16 | — | — | CN | disclosed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | disclosed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | disclosed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367580-A1 | IMPROVED EXTENDED-ACTION TILMICOSIN AND USE THEREOF IN TREATMENT OF BOVINE RESPIRATORY DISEASE COMPLEX (BRD) AND IN DRY COW PERIOD | BTD, LTA, SBDS | NR1I2 2486/4885MAPT 1240/4885TDP1 2322/4885 |
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | OPRL1, OPRK1, SIGMAR1 | NR1I2 378/4885MAPT 3625/4885TDP1 2716/4885 |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | OPRL1, OPRK1, OPRM1 | NR1I2 119/4885MAPT 1420/4885TDP1 4291/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | NR1I2 793/4885MAPT 917/4885TDP1 3956/4885 |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | SIGMAR1, GPR119, TMEM97 | NR1I2 53/4885MAPT 3205/4885TDP1 4408/4885 |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | SIGMAR1, SFN, TMEM97 | NR1I2 177/4885MAPT 4002/4885TDP1 1095/4885 |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | SIGMAR1, OPRL1, OPRK1 | NR1I2 37/4885MAPT 4337/4885TDP1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.